Fighting antimicrobial resistant infections by high-throughput discovery of biofilm-disrupting agents and mechanisms
Therapeutics
- Morten Kjos, Norwegian University of Life Sciences, Norway (Coordinator)
- Jan-Willem Veening, University of Lausanne, Switzerland (Partner)
- Athanasios Typas, European Molecular Biology Laboratory, Germany (Partner)
- Christoph Merten, European Molecular Biology Laboratory, Germany (Partner)
Antimicrobial resistance is a growing problem worldwide. Many bacterial infections are nowadays often difficult to treat due to increasing antimicrobial resistance. Infections are particularly problematic if they are associated with biofilms. Biofilms are structured communities of bacteria, which are attached to surfaces. Infections typically caused by biofilms are wound-infections and urinary tract infections. The surface-attached biofilms are held together by a slimy matrix of polysaccharides, lipids, DNA and proteins. The matrix protects the bacterial cells against antibiotics and adds to the already existing resistance, making the infection treatment highly problematic. Novel strategies to treat such infections are therefore critical. In our project we focus on four bacteria which has been listed as high-priority pathogens by WHO. These are (1) uropathogenic E. coli (the major cause of urinary tract infections and catheher infections), (2) Pseudomonas aeruginosa (whose biofilms are associated with chronic infections in wounds or during cystic fibrosis), (3) Staphylococcus aureus (causing biofilm-associated chronic wound - and medical implant infections), and (4) Streptococcus pneumoniae (whose biofilms have been associated with middle-ear infections and pneumoniae). The DISRUPT project aims to identify new strategies to treat biofilm-associated infections. By inhibiting bacterial biofilms, the chances of infections will be reduced, and this will also resensitize the bacteria to existing antibiotics. To do this, we are using state-of-the-art genetic technologies (transposon sequencing, CRISPR interference) combined with high-throughput screens (screen for chemicals and microfluidic antibody screens) to identify anti-biofilm agents and mechanisms. The methods and resources we develop will be available for researchers worldwide, and will positively impact a range of research project related to AMR pathogens.
- Microbiology Spectrum, 2024. Development of an inducer-free, virulence gene promoter-controlled, and fluorescent reporter-labeled CRISPR interference system in Staphylococcus aureus
- bioRxiv, 2022. Competence remodels the pneumococcal cell wall providing resistance to fratricide and surface exposing key virulence factors
- Nature Protocols, 2023. Design and construction of a microfluidics workstation for high-throughput multi-wavelength fluorescence and transmittance activated droplet analysis and sorting
- PeerJ, 2022. 2FAST2Q: a general-purpose sequence search and counting program for FASTQ files
- Cell Reports, 2022. Pneumolysin promotes host cell necroptosis and bacterial competence during pneumococcal meningitis as shown by whole-animal dual RNA-seq
- bioRxiv - December 2022. High-throughput profiling of drug interactions in Gram-positive bacteria
- Current Opinion in Microbiology, 2023. Gaps in the wall: understanding cell wall biology to tackle amoxicillin resistance in Streptococcus pneumoniae
- Nature Microbiology, 2023. Systematic analysis of drug combinations against Gram-positive bacteria
- Nature Structural & Molecular Biology, 2020. Structure of a proton-dependent lipid transporter involved in lipoteichoic acids biosynthesis
- MicrobiologyOpen, 2020. Penicillin‐binding protein PBP2a provides variable levels of protection toward different b‐lactams in Staphylococcus aureus RN4220
- eLife, 2020. Unbiased homeologous recombination during pneumococcal transformation allows for multiple chromosomal integration events
- Cell Host & Microbe, 2020. Exploration of Bacterial Bottlenecks and Streptococcus pneumoniae Pathogenesis by CRISPRi-Seq
- PNAS, 2020. Synthetic gene-regulatory networks in the opportunistic human pathogen Streptococcus pneumoniae
- mBio, 2020. A CozE Homolog Contributes to Cell Size Homeostasis of Streptococcus pneumoniae
- Nature Microbiology, 2021. CcrZ is a pneumococcal spatiotemporal cell cycle regulator that interacts with FtsZ and controls DNA replication by modulating the activity of DnaA
- Microbiology Spectrum, 2021. Ubericin K, a New Pore-Forming Bacteriocin Targeting mannose-PTS.
- Biophysical Journal, 2021. Switching off: the phenotypic transition to the uninduced state of the lactose uptake pathway
- Nature Protocols, 2022. CRISPRi-seq for genome-wide fitness quantification in bacteria
- Appl Environ Microbiol, 2020. Harnessing CRISPR-Cas9 for genome editing in Streptococcus pneumoniae D39V
- Science Advances, 2022. Mechanistic basis of choline import involved in teichoic acids and lipopolysaccharide modification
- Cell Host Microbe, 2021. Exploration of Bacterial Bottlenecks and Streptococcus pneumoniae Pathogenesis by CRISPRi-Seq.
- Elife, 2022. Amoxicillin-resistant Streptococcus pneumoniae can be resensitized by targeting the mevalonate pathway as indicated by sCRilecs-seq.
- Nat Protoc, 2022. CRISPRi-seq for genome-wide fitness quantification in bacteria.
- mBio, 2022. SmdA is a Novel Cell Morphology Determinant in Staphylococcus aureus.
- Antibiotics (Basel), 2021. Staphylococcal Biofilms: Challenges and Novel Therapeutic Perspectives.
- PNAS, 2024. Fluorescence-activated droplet sequencing (FAD-seq) directly provides sequences of screening hits in antibody discovery
- 2FAST2Q
A general-purpose sequence search and counting program for FASTQ files. - 2FAST2Q
A Python3 program that counts sequence occurrences in raw FASTQ files. - Droplet microfluidic screening platform
A droplet microfluidic screening platform that can also be run in transmission mode with all design files and software for setting up the technology in further labs
